PARIS, Sept 20 – Over the past few months analysts and experts have been scratching their heads, wondering if leading proteomics company Oxford Glycosciences (LSE: OGS) was losing its edge.

The company appeared to have a poor business plan, a weak drug development pipeline, and little response as companies such as Celera Genomics (NYSE: CRA) and Swiss start-up Geneva Proteomics announced their intentions to dominate the proteomics space.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.